Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model

Journal of Drug Targeting

Volumn 16, Issue 9, 2008, Pages 679-687

  Zhang, Yongming ^a   Li, Aidong ^a   Wang, Zheng ^a   Han, Zhikai ^a   He, Jie ^a   Ma, Jie ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Amputation; Metastasis; Pegylated liposomal doxorubicin

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; C57BL 6 MOUSE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; LIMB AMPUTATION; LIMB TUMOR; LUNG METASTASIS; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; SOFT TISSUE NEOPLASMS;

EID: 55849096936     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860802201340     Document Type: Article

References (38)

1. Alexopoulos, A., Karamouzis, MV, Stavirinides, H., Ardavanis, A., Kandilis, K., Stavrakakis, J., Georganta, C. and Rigatos, G. (2004) Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol, 15, pp. 891-895.
2. Allen, TM and Cullis, PR (2004) Drug delivery system: Entering the mainstream. Science, 303, pp. 1818-1822.
3. Allen, TM, Hansen, CB and Lopes de Menezes, DE (1995) Pharmacokinetics of long-circulating liposomes. Adv Drug Del Rev, 16, pp. 267-284.
4. Bartlett, GR (1959) Phosphorus assay in column chromatography. J Biol Chem, 234, pp. 466-468.
5. Bocci, G., Nicolaou, KC and Kerbel, RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res, 62, pp. 6938-6943.
6. Cabanes, A., Tzemach, D., Geren, D., Horowitz, AT and Gabizon, A. (1998) Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res, 4, pp. 499-505.
7. Chan, S., Davidson, N., Juozaityte, E., Erdkamp, F., Pluzanska, A., Azarnia, N. and Lee, LW (2004) Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol, 15, pp. 1527-1534.
8. Chao, T., Wang, W., Yen, C., Chiou, T., Liu, J. and Chen, P. (2003) A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer. Cancer Invest, 21, pp. 837-847.
9. Colbern, GT, Hiller, AJ, Musterer, RS, Pegg, E., Henderson, C. and Working, PK (1999) Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes. J Liposome Res, 9, pp. 523-538.
10. Drummond, DC, Meyer, O., Hong, K., Kirpotin, DB and Papahadjopoulos, D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 51, pp. 691-743.
11. Gabizon, AA (2001) Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest, 19, pp. 424-436.
12. Gabizon, AA, Barenholz, Y. and Bialer, M. (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharm Res, 10, pp. 703-708.
13. Gorelik, E., Segel, S. and Feldman, M. (1980) Control of lung metastasis progression in mice: Role of growth kinetics of 3LL Lewis lung carcinoma and host immune activity. J Natl Cancer Inst, 65, pp. 1257-1264.
14. Haran, G., Cohen, R., Bar, LK and Barenholz Y (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta, 1151, pp. 201-215.
15. Kerbel, RS, Klement, G., Pritchard, KI and Kamen, B. (2002) Continuous low-dose anti-angiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol, 13, pp. 12-15.
16. Kimura, Y. and Sumiyoshi, M. (2005) Antitumor and antimetastatic actions of eicocapentaenoic acid ethylester and its by-products formed during accelerated stability testing. Cancer Sci, 96, pp. 441-450.
17. Koshkina, NV, Kleinerman, ES, Waldrep, C., Jia, SF, Worth, LL, Gilbert, BE and Knight, V. (2000) 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res, 6, pp. 2876-2880.
18. Koshkina, NV, Waldrep, JC, Roberts, LE, Golunski, E., Melton, S. and Knight, V. (2001) Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res, 7, pp. 3258-3262.
19. Krishnan, K., Khanna, C. and Helman, LJ (2006) The molecular biology of pulmonary metastasis. Thorac Surg Clin, 16, pp. 115-124.
20. Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, NI, Lotem, M., Brufman, G. and Gabizon, A. (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer, 89, pp. 1037-1047.
21. Moase, EH, Qi, W., Ishida, T., Gabos, Z., Longenecker, BM, Zimmermann, GL, Ding, L., Krantz, M. and Allen, TM (2001) Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophy Acta, 1510, pp. 43-55.
22. Mrozek, E., Rhoades, CA, Allen, J., Hade, EM and Shapiro, CL (2005) Phase I trial of liposomal encapsulated doxorubicin (MyocetTM; D-99) and weekly docetaxel in advanced breast cancer patients. Ann Oncol, 16, pp. 1087-1093.
23. Muggia, F. (2003) Doxorubicin for metastatic breast cancer: Time for a change?. Cancer Invest, 21, pp. 967-968.
24. Murray, JC and Moghimi, SM (2003) Endothelial cells as therapeutic targets in cancer: New biology and novel delivery system. Crit Rev Ther Drug Carrier Syst, 20, pp. 139-152.
25. Nguyen, TH (2004) Mechanisms of metastasis. Clin Dermatol, 22, pp. 209-216.
26. Papahadjopoulos, D., Allen, TM, Gabizon, A., Mayhew, E., Matthay, K., Huang, SK, Lee, KD, Woodle, MC, Lasic, DD, Redemann, C. and Martin, FJ (1991) Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A, 88, pp. 11460-11464.
27. Parr, MJ, Ansell, SM, Choi, LS and Cullis, PR (1994) Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim Biophys Acta, 1195, pp. 21-30.
28. Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., Allen, TM, Corti, A. and Ponzoni, M. (2003) Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res, 63, pp. 7400-7409.
29. Rivera, E., Valero, V., Arun, B., Royce, M., Adinin, R., Hoelzer, K., Walters, R., Wade, JL, Pusztai, L. and Hortobagyi, GN (2003) Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol, 21, pp. 3249-3254.
30. Sakakibara, T., Chen, F., Kida, H., Kunieda, K., Cuenca, RE, Martin, FJ and Bankert, RB (1996) Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing convertional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res, 56, pp. 3743-3746.
31. Song, H., Zhang, J., Han, Z., Zhang, X., Li, Z., Zhang, L., Fu, M., Lin, C. and Ma, J. (2006) Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. Cancer Chemother Pharmacol, 57, pp. 591-598.
32. Straubinger, R., Arnold, RD, Zhou, R., Mazurchuk, R. and Slack, JE (2004) Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res, 24, pp. 397-404.
33. Strieth, S., Eichhorn, ME, Sauer, B., Schulze, B., Teifel, M., Michaelis, U. and Dellian, M. (2004) Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer, 110, pp. 117-124.
34. Torchilin, VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 4, pp. 145-160.
35. Vaage, J., Mayhew, E., Lasic, D. and Martin, F. (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer, 51, pp. 942-948.
36. Vaage, J., Donovan, D., Loftus, T. and Working, P. (1995) Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin. Br J Cancer, 72, pp. 1074-1075.
37. Yoneda, KY, Louie, S. and Shelton, DK (2000) Approach to pulmonary metastases. Curr Opin Pulm Med, 6, pp. 356-363.
38. Zhou, R., Mazurchuk, R. and Straubinger, RM (2002) Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res, 62, pp. 2561-2566.